Reports Q2 revenue $189.7M, consensus $186.82M. “I’m encouraged by the progress made during the second quarter,” said Scott Wagner, Interim CEO. “We exceeded our Revenue and Adjusted EBITDA expectations with prescription transactions revenue and volume returning to year-over-year growth. We expanded the number of direct contracts we have with pharmacies, announced an exciting new program with CVS Caremark, and continued to align our teams and people against our biggest opportunities. Looking ahead, we are focused on rebuilding momentum in the business financially and operationally with an eye toward compounding growth in 2024 and beyond.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GDRX:
- Notable companies reporting before tomorrow’s open
- Adobe upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- GoodRx upgraded to Outperform at TD Cowen after ‘game changer’ PBM partnerships
- GoodRx upgraded to Outperform from Market Perform at TD Cowen
- GoodRx price target raised to $8 from $6 at Morgan Stanley